SKYA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-07

• Since our inception in 2017 and through 2022, we devoted substantially all of our resources to the research and development of our safety syringe products. Commencing in 2022,` we started building inventory of syringe products. We commenced generating syringe revenues in 2025. In October 2025, we di…

• In August 2025, we adopted a digital commodity treasury strategy focused on accumulating Solana (“SOL”), the native digital commodity of the Solana blockchain. The Company earns staking rewards by delegating our digital commodities to third-party validators on proof-of-stake blockchain networks.

• For the three and six months ended June 30, 2026, we reported a net loss of approximately $23.3 million and $109.5 million, primarily resulting from unrealized and realized losses on our Solana holdings of approximately $84.3 million and $14.7 million, respectively.

• Our Medical Device segment has net revenues, cost of goods sold and gross margin/loss. We also have staking revenue from our Digital Commodities segment. Operating expenses include transaction expenses relating to digital commodity activities, research and development for our software under developm…

• Substantially all of our research and development expenses to date have been incurred in connection with our syringe products. Following the transfer by the Company of certain assets, the Company is no longer engaged in medical device related research and development activities and is limiting its m…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Since our inception in 2017 and through the fourth quarter of 2022, we devoted substantially all of our resources to the research and development of our safety syringe products. Commencing in the fourth quarter of 2022 we started building inventory of syringe products. We commenced generating syring…

• We classify our revenues as net revenues, cost of goods sold and gross margin/loss from our Medical Device segment and staking revenue from digital commodities segment. Operating expenses include transaction expenses relating to digital commodity activities, research and development from medical dev…

• We continue to be in discussions with healthcare companies and distributors for sales of our existing inventory of disposable syringe products. We continue to market these products to prospective customers, which include foreign governments, hospitals and healthcare groups as opportunities present t…

• Substantially all of our research and development expenses to date have been incurred in connection with our syringe products. Following the transfer by the Company of certain assets, and a contract for the transfer of business share providing for the assignment by the Company of all of the Company’…

• On January 10, 2026, we executed a short-term lease for a 3,116 square foot office facility in Shenzhen, China to serve as the temporary headquarters of our Asia-based operations. On May 2, 2026 we were able to lease a 1,467 square foot office in Hong Kong to serve as the permanent headquarters for …

Text added vs the prior filing · source: 10-Q · 2026-08-07

• We have recently undergone a fundamental transformation of our business and strategic direction, and there can be no assurance that our new strategy will be successful.

• Beginning in the second quarter of 2026, we discontinued our legacy business of marketing and distribution of syringe products and related drug-delivery systems, and adopted a new business strategy focused on building an agentic finance platform serving the global south. We have limited operating hi…

• Our use and integration of AI, including generative AI, in connection with our Solana treasury strategy and broader business operations expose us to operational, legal, regulatory, reputational, and competitive risks.

• AI technologies, particularly generative AI, remain in relatively early stages of commercial deployment and are inherently complex and rapidly evolving. These technologies may produce inaccurate, incomplete, misleading, or “hallucinatory” outputs and may embed unintended biases or discriminatory or …

• In addition, our reliance on AI-powered tools may increase the risk of inadvertent disclosure or misuse of confidential or proprietary information. If our employees, contractors, or service providers input sensitive information into third-party AI systems, such information could become part of exter…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• As part of its review of our corporate governance policies, on May 8, 2026, the board of directors approved and adopted the Code Of Business Conduct And Ethics (the “Code of Ethics”), which governs the conduct of all officers, directors, and employees of the Company and its affiliated entities. The …

• On May 13, 2026, the Company entered into an employment agreement (the “Danner Employment Agreement”) with Paul Danner, which replaces and supersedes in its entirety that certain prior employment agreement, dated August 25, 2025, between the Company and Mr. Danner. Pursuant to the Employment Agreeme…

• On May 13, 2026, the Company entered into an employment agreement (the “Zhang Employment Agreement”) with Yuwen Zhang, which replaces and supersedes in its entirety that certain prior employment agreement, dated August 25, 2025, between the Company and Ms. Zhang. Pursuant to the Employment Agreement…

• On May 13, 2026, the Board of Directors (the “Board”) of Sharps Technology, Inc. (the “Company”):

• ●adopted a limited duration stockholder rights plan (the “Rights Plan”), the terms of which are set forth in a Rights Agreement entered into between the Company and VStock Transfer, LLC, as rights agent (the “Rights Agent”) dated May 14, 2026; and